Successful Dostarlimab Rechallenge Following Pembrolizumab‐Induced Autoimmune Hemolytic Anemia: A Case Report

ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering durable responses across multiple malignancies. However, these agents can trigger severe immune‐related adverse events (irAEs), including drug‐induced autoimmune hemolytic anemia (AIHA), which often necessita...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Zaid Khamis, Kai Wang, Mohammad Aldalahmeh, Salim Barakat, Nawaraj Adhikari, Raghad Khassawneh, Bhavya Misri, Dhar Meekoo
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2025-08-01
Edice:	Clinical Case Reports
Témata:	adverse immune events autoimmune hemolytic anemia checkpoint inhibitor rechallenge dostarlimab immune checkpoint inhibitors pembrolizumab
On-line přístup:	https://doi.org/10.1002/ccr3.70776
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!